In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Akubio Ltd.

Executive Summary

Founded in 2001, Akubio Ltd. is one company seeking to tap the commercial potential of acoustic detection technology in drug discovery and development, as well as diagnostics. The company's Rupture Event Scanning (REVS) and Resonant Acoustic Profiling (RAP) platforms can be used to detect not only large molecules like viruses and bacterial cells, but also small molecule drugs, proteins or oligonucleotides. As well as being simpler, faster and cheaper than other detection technologies such as PCR and ELISA, Akubio's platforms can also generate information on the binding affinities and kinetics of molecules' interactions with their receptors.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts